<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00510835</url>
  </required_header>
  <id_info>
    <org_study_id>P50GM076659</org_study_id>
    <nct_id>NCT00510835</nct_id>
  </id_info>
  <brief_title>Protocolized Care for Early Septic Shock</brief_title>
  <acronym>ProCESS</acronym>
  <official_title>Protocolized Care for Early Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ProCESS study is large, 5-year, multicenter study of alternative resuscitation strategies
      for septic shock. The study hypothesizes that there are &quot;golden hours&quot; in the initial
      management of septic shock where prompt, rigorous, standardized care can improve clinical
      outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Septic shock is a condition of acute organ dysfunction due to severe infection, with a
      mortality of up to 50%. Current efforts to improve care are limited by little practical
      evidence regarding the interventions in and timing of sepsis therapies. ProCESS is a
      prospective, randomized, three-arm parallel-group trial of alternative resuscitation
      strategies for early septic shock. The study objective is to improve the management of septic
      shock by exploring the clinical, biological, and economic aspects of alternative
      resuscitation strategies. This will be done by comparing two alternative resuscitation
      strategies to usual care in subjects with septic shock.

      Comparisons:

        1. Early Goal Directed Therapy (EGDT) - The subjects' blood pressure and blood oxygen
           levels will be monitored via the insertion of a central venous catheter (CVC). The study
           team will use this information to give fluid, blood and heart medications in a
           structured fashion. The central venous catheter to be used in this plan is FDA approved
           and routinely used in hospitals.

        2. Protocolized Standard Care (PSC) - The subjects' blood pressure and blood oxygen levels
           will be monitored with standard equipment (without the CVC). The study team will use
           this information to prescribe fluid and heart medications in a structured fashion. CVCs
           will only be used when standard IVs cannot give the proper amount of fluids and
           medicines. Blood transfusions will be given according to currently recommended
           guidelines.

        3. Usual Care (UC) - Subjects will be treated according to their attending physician's
           standard treatment plan and without any influence from the study team.

      The primary hypotheses to be tested sequentially are that: protocolized resuscitation (EGDT
      and PSC) results in lower hospital mortality than usual care and Early Goal Directed Therapy
      results in lower hospital mortality than Protocolized Standard Care. These hypotheses will be
      tested on all enrolled subjects.

      The study is powered to find an absolute mortality reduction (ARR) of ~6-7%. Based on the
      control arm mortality rate, we originally estimated a sample size of 1950. During the trial,
      the ProCESS Coordinating Center monitored the overall mortality rate, and appreciated that it
      was markedly lower than originally projected. Therefore, following a series of new
      calculations, in February 2013, the trial was re-sized to 1350 patients (450 patients per
      arm). The new size preserves the same power to find the same ARR. The resizing was fully
      blinded and approved by the NIH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>prior to discharge or 60 days, whichever comes first</time_frame>
    <description>The primary study outcome is hospital mortality (defined as the number of deaths prior to discharge or 60 days, whichever comes first). The secondary outcomes are duration of survival (90 day and 1 year) and clinical evidence of organ dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Markers of Inflammation, Oxidative Stress, Cellular Hypoxia and Coagulation/Thrombosis.</measure>
    <time_frame>study hour 0, 6, 24 &amp; 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Use and Costs of Alternative Resuscitation Strategies</measure>
    <time_frame>at discharge or 60 days, whichever comes first</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1351</enrollment>
  <condition>Sepsis</condition>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early Goal Directed Therapy (EGDT) - The study team will insert a central venous catheter (CVC) for continuous monitoring of the subjects' central venous pressure (CVP) and central venous oxygen saturation (Scv02). The study team will use this information to give fluid, blood, and heart medications in a structured fashion. The CVC is FDA approved and routinely used in hospitals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocolized Standard Care (PSC)- The study team will monitor the subjects' blood pressure and blood oxygen level with routine equipment. The study team will use this information to give fluid and heart medications in a structured fashion. CVCs will only be used when standard IVs are unable to give the proper amount of fluids and medicines. Blood transfusions will be given according to currently recommended guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual Care - The attending physicians will treat the subjects according to their standard treatment plan and without any influence from the study team. A member of the study team will simply observe and record what happens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Early Goal Directed Therapy (EGDT)</intervention_name>
    <description>Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Protocolized Standard Care (PSC)</intervention_name>
    <description>Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Usual Care (UC)</intervention_name>
    <description>Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  At least 18 years of age

          -  Suspected infection

          -  Two or more systemic inflammatory response syndrome (SIRS) criteria

               -  Temperature &lt;/= 36˚ C or &gt;/= 38˚C

               -  Heart rate &gt;/= 90 beats per minute

               -  Mechanical ventilation for acute respiratory process or respiratory rate &gt;/= 20
                  breaths per minute or PaC02 &lt; 32 mmHg

               -  WBC &gt;/= 12,000/mm³ OR &lt;/= 4,000/mm³ OR &gt; 10% bands

          -  Refractory hypotension (a systolic blood pressure &lt; 90 mm Hg despite an IV fluid
             challenge of at least 1,000 mLs over a 30 minute period) or evidence of hypoperfusion
             (a blood lactate concentration &gt;/= 4 mmol/L)

        Exclusion criteria:

          -  Known pregnancy

          -  Primary diagnosis of acute cerebral vascular event, acute coronary syndrome, acute
             pulmonary edema, status asthmaticus, major cardiac arrhythmia, active gastrointestinal
             hemorrhage, seizure, drug overdose, burn or trauma

          -  Requirement for immediate surgery

          -  ANC &lt; 500/mm³

          -  CD4 &lt; 50/mm³

          -  Do-not-resuscitate status

          -  Advanced directives restricting implementation of the protocol

          -  Contraindication to central venous catheterization

          -  Contradiction to blood transfusion (e.g., Jehovah's Witness)

          -  Treating physician deems aggressive care unsuitable

          -  Participation in another interventional study

          -  Transferred from another in-hospital setting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek C. Angus, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John A. Kellum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald M. Yealy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA County &amp; USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center/Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York - Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Health System</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304-1619</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey College of Medicine; Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Shadyside Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Brackenridge</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://crisma.upmc.com/processtrial/info2.asp</url>
    <description>ProCESS Study Web Site</description>
  </link>
  <reference>
    <citation>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77.</citation>
    <PMID>11794169</PMID>
  </reference>
  <reference>
    <citation>Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10.</citation>
    <PMID>11445675</PMID>
  </reference>
  <reference>
    <citation>Kochanek KD, Smith BL. Deaths: preliminary data for 2002. Natl Vital Stat Rep. 2004 Feb 11;52(13):1-47.</citation>
    <PMID>14998175</PMID>
  </reference>
  <reference>
    <citation>O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979 Sep;35(3):549-56.</citation>
    <PMID>497341</PMID>
  </reference>
  <reference>
    <citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644-55. Review.</citation>
    <PMID>1303622</PMID>
  </reference>
  <reference>
    <citation>Rivers EP, Ander DS, Powell D. Central venous oxygen saturation monitoring in the critically ill patient. Curr Opin Crit Care. 2001 Jun;7(3):204-11. Review.</citation>
    <PMID>11436529</PMID>
  </reference>
  <reference>
    <citation>Feezor RJ, Baker HV, Mindrinos M, Hayden D, Tannahill CL, Brownstein BH, Fay A, MacMillan S, Laramie J, Xiao W, Moldawer LL, Cobb JP, Laudanski K, Miller-Graziano CL, Maier RV, Schoenfeld D, Davis RW, Tompkins RG; Inflammation and Host Response to Injury, Large-Scale Collaborative Research Program. Whole blood and leukocyte RNA isolation for gene expression analyses. Physiol Genomics. 2004 Nov 17;19(3):247-54.</citation>
    <PMID>15548831</PMID>
  </reference>
  <reference>
    <citation>Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med. 1997 Aug 15;127(4):257-66.</citation>
    <PMID>9265424</PMID>
  </reference>
  <reference>
    <citation>Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, Sexton B, Hyzy R, Welsh R, Roth G, Bander J, Kepros J, Goeschel C. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006 Dec 28;355(26):2725-32. Erratum in: N Engl J Med. 2007 Jun 21;356(25):2660.</citation>
    <PMID>17192537</PMID>
  </reference>
  <reference>
    <citation>McGee WT, Ackerman BL, Rouben LR, Prasad VM, Bandi V, Mallory DL. Accurate placement of central venous catheters: a prospective, randomized, multicenter trial. Crit Care Med. 1993 Aug;21(8):1118-23.</citation>
    <PMID>8339574</PMID>
  </reference>
  <reference>
    <citation>Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts--blood transfusion. N Engl J Med. 1999 Feb 11;340(6):438-47. Review.</citation>
    <PMID>9971869</PMID>
  </reference>
  <reference>
    <citation>Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002 Aug;42(8):975-9.</citation>
    <PMID>12385406</PMID>
  </reference>
  <reference>
    <citation>Dellinger RP. Cardiovascular management of septic shock. Crit Care Med. 2003 Mar;31(3):946-55. Review.</citation>
    <PMID>12627010</PMID>
  </reference>
  <reference>
    <citation>Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, Heard SO, Martin C, Napolitano LM, Susla GM, Totaro R, Vincent JL, Zanotti-Cavazzoni S. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004 Sep;32(9):1928-48. Review.</citation>
    <PMID>15343024</PMID>
  </reference>
  <reference>
    <citation>Rady MY, Smithline HA, Blake H, Nowak R, Rivers E. A comparison of the shock index and conventional vital signs to identify acute, critical illness in the emergency department. Ann Emerg Med. 1994 Oct;24(4):685-90. Erratum in: Ann Emerg Med 1994 Dec;24(6):1208.</citation>
    <PMID>8092595</PMID>
  </reference>
  <reference>
    <citation>Yealy DM, Delbridge TR. The shock index: all that glitters... Ann Emerg Med. 1994 Oct;24(4):714-5.</citation>
    <PMID>8092601</PMID>
  </reference>
  <reference>
    <citation>Rady MY, Rivers EP, Nowak RM. Resuscitation of the critically ill in the ED: responses of blood pressure, heart rate, shock index, central venous oxygen saturation, and lactate. Am J Emerg Med. 1996 Mar;14(2):218-25.</citation>
    <PMID>8924150</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2007</study_first_submitted>
  <study_first_submitted_qc>August 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2007</study_first_posted>
  <results_first_submitted>December 1, 2016</results_first_submitted>
  <results_first_submitted_qc>December 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2017</results_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Derek C. Angus, MD, MPH</investigator_full_name>
    <investigator_title>Chair, Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>resuscitation</keyword>
  <keyword>sepsis</keyword>
  <keyword>cost-effectiveness</keyword>
  <keyword>sepsis-induced organ dysfunction</keyword>
  <keyword>early goal directed therapy</keyword>
  <keyword>emergency medicine</keyword>
  <keyword>critical care medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Early Goal Directed Therapy (EGDT)</title>
          <description>Early Goal Directed Therapy (EGDT) - The study team will insert a central venous catheter (CVC) for continuous monitoring of the subjects' central venous pressure (CVP) and central venous oxygen saturation (Scv02). The study team will use this information to give fluid, blood, and heart medications in a structured fashion. The CVC is FDA approved and routinely used in hospitals.
Early Goal Directed Therapy (EGDT): Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.</description>
        </group>
        <group group_id="P2">
          <title>Protocolized Standard Care (PSC)</title>
          <description>Protocolized Standard Care (PSC)- The study team will monitor the subjects' blood pressure and blood oxygen level with routine equipment. The study team will use this information to give fluid and heart medications in a structured fashion. CVCs will only be used when standard IVs are unable to give the proper amount of fluids and medicines. Blood transfusions will be given according to currently recommended guidelines.
Protocolized Standard Care (PSC): Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.</description>
        </group>
        <group group_id="P3">
          <title>Usual Care</title>
          <description>Usual Care - The attending physicians will treat the subjects according to their standard treatment plan and without any influence from the study team. A member of the study team will simply observe and record what happens.
Usual Care (UC): Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="445"/>
                <participants group_id="P2" count="448"/>
                <participants group_id="P3" count="458"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="439"/>
                <participants group_id="P2" count="446"/>
                <participants group_id="P3" count="456"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early Goal Directed Therapy (EGDT)</title>
          <description>Early Goal Directed Therapy (EGDT) - The study team will insert a central venous catheter (CVC) for continuous monitoring of the subjects' central venous pressure (CVP) and central venous oxygen saturation (Scv02). The study team will use this information to give fluid, blood, and heart medications in a structured fashion. The CVC is FDA approved and routinely used in hospitals.
Early Goal Directed Therapy (EGDT): Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.</description>
        </group>
        <group group_id="B2">
          <title>Protocolized Standard Care (PSC)</title>
          <description>Protocolized Standard Care (PSC)- The study team will monitor the subjects' blood pressure and blood oxygen level with routine equipment. The study team will use this information to give fluid and heart medications in a structured fashion. CVCs will only be used when standard IVs are unable to give the proper amount of fluids and medicines. Blood transfusions will be given according to currently recommended guidelines.
Protocolized Standard Care (PSC): Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.</description>
        </group>
        <group group_id="B3">
          <title>Usual Care</title>
          <description>Usual Care - The attending physicians will treat the subjects according to their standard treatment plan and without any influence from the study team. A member of the study team will simply observe and record what happens.
Usual Care (UC): Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="439"/>
            <count group_id="B2" value="446"/>
            <count group_id="B3" value="456"/>
            <count group_id="B4" value="1341"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="16.4"/>
                    <measurement group_id="B2" value="61" spread="16.1"/>
                    <measurement group_id="B3" value="62" spread="16.0"/>
                    <measurement group_id="B4" value="61" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="593"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="264"/>
                    <measurement group_id="B4" value="748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="439"/>
                    <measurement group_id="B2" value="446"/>
                    <measurement group_id="B3" value="456"/>
                    <measurement group_id="B4" value="1341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hospital Mortality</title>
        <description>The primary study outcome is hospital mortality (defined as the number of deaths prior to discharge or 60 days, whichever comes first). The secondary outcomes are duration of survival (90 day and 1 year) and clinical evidence of organ dysfunction.</description>
        <time_frame>prior to discharge or 60 days, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Goal Directed Therapy (EGDT)</title>
            <description>Early Goal Directed Therapy (EGDT) - The study team will insert a central venous catheter (CVC) for continuous monitoring of the subjects' central venous pressure (CVP) and central venous oxygen saturation (Scv02). The study team will use this information to give fluid, blood, and heart medications in a structured fashion. The CVC is FDA approved and routinely used in hospitals.
Early Goal Directed Therapy (EGDT): Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.</description>
          </group>
          <group group_id="O2">
            <title>Protocolized Standard Care (PSC)</title>
            <description>Protocolized Standard Care (PSC)- The study team will monitor the subjects' blood pressure and blood oxygen level with routine equipment. The study team will use this information to give fluid and heart medications in a structured fashion. CVCs will only be used when standard IVs are unable to give the proper amount of fluids and medicines. Blood transfusions will be given according to currently recommended guidelines.
Protocolized Standard Care (PSC): Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.</description>
          </group>
          <group group_id="O3">
            <title>Usual Care</title>
            <description>Usual Care - The attending physicians will treat the subjects according to their standard treatment plan and without any influence from the study team. A member of the study team will simply observe and record what happens.
Usual Care (UC): Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality</title>
          <description>The primary study outcome is hospital mortality (defined as the number of deaths prior to discharge or 60 days, whichever comes first). The secondary outcomes are duration of survival (90 day and 1 year) and clinical evidence of organ dysfunction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="439"/>
                <count group_id="O2" value="446"/>
                <count group_id="O3" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Markers of Inflammation, Oxidative Stress, Cellular Hypoxia and Coagulation/Thrombosis.</title>
        <time_frame>study hour 0, 6, 24 &amp; 72</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Use and Costs of Alternative Resuscitation Strategies</title>
        <time_frame>at discharge or 60 days, whichever comes first</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported following the protocol guidelines: 1. Detailed information was collected regarding all SAEs that occurred during ProCESS study hours 0-72 2. Ongoing SAE information was collected for events related to the study PreSep line for the duration of the hospital stay or day 60 (whichever came 1st) 3. After hour 72, all SAEs that investigators considered potentially related to the study intervention were collected.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Early Goal Directed Therapy (EGDT)</title>
          <description>Early Goal Directed Therapy (EGDT) - The study team will insert a central venous catheter (CVC) for continuous monitoring of the subjects' central venous pressure (CVP) and central venous oxygen saturation (Scv02). The study team will use this information to give fluid, blood, and heart medications in a structured fashion. The CVC is FDA approved and routinely used in hospitals.
Early Goal Directed Therapy (EGDT): Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.</description>
        </group>
        <group group_id="E2">
          <title>Protocolized Standard Care (PSC)</title>
          <description>Protocolized Standard Care (PSC)- The study team will monitor the subjects' blood pressure and blood oxygen level with routine equipment. The study team will use this information to give fluid and heart medications in a structured fashion. CVCs will only be used when standard IVs are unable to give the proper amount of fluids and medicines. Blood transfusions will be given according to currently recommended guidelines.
Protocolized Standard Care (PSC): Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.</description>
        </group>
        <group group_id="E3">
          <title>Usual Care</title>
          <description>Usual Care - The attending physicians will treat the subjects according to their standard treatment plan and without any influence from the study team. A member of the study team will simply observe and record what happens.
Usual Care (UC): Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>hemorrhage/bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <description>Pain NOS</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatobiliary/pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/laboratory</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neurology</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal/genitourinary</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>vascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>blood/bone marrow</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>coagulation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>lymphatics</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>endocrine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ocular/visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>hemorrhage/bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatobiliary/pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergy/immunology</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>metabolic/laboratory</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neurology</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal/genitourinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatology/skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>hematoma</sub_title>
                <description>While remaining in the ICU, the subject developed a large hematoma in the right groin at the site of the femoral line and the line was removed. As this arm of the study is observational only this adverse event is considered unrelated to the study.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Line issue</sub_title>
                <description>Old line removed but unable to thread new line resulting in loss of CVL. Unable to access R IJ as shunt in place. Pt was to have central line surgically for hypotension, places upon admission to ICU and was determined not meet the criteria for SAE.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>vascular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Derek C. Angus, MD, MPH, FRCP</name_or_title>
      <organization>UPittsburgh</organization>
      <phone>(412) 647-6965</phone>
      <email>angusdc@ccm.upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

